Aratana Connects with Veterinary Professionals at WVC Conference 2016

At the Intersection of Human Science and Veterinary Medicine, Aratana Therapeutics is continuing its mission of bringing new therapeutics to help raise the standard of care for pets. At the Western Veterinary Conference 2016, Aratana sponsored 12 scientific CE sessions and interacted with thousands of veterinary professionals at their exhibit booth to introduce the emerging therapeutics they are bringing to the market. Their three lead therapeutics are anticipated to receive FDA-approval in 2016 and are focused on the control of pain and inflammation in dogs with osteoarthritis, extended post-operative pain-relief for knee surgery in dogs and inappetence in dogs. The company also sponsored a session reviewing a stem cell therapy being pursued for osteoarthritis. In other sessions, Aratana presented on USDA-licensed products that may aid in the treatment of lymphoma, along with a vaccine that is in development for dogs diagnosed with osteosarcoma.

Aratana made a strong connection with over 1,600 veterinary professionals at their sponsored CE sessions and generated excitement about the anticipated approval of their EP4 PRA osteoarthritis pain management therapeutic and their inappetence therapeutic.

Julia Stephanus, Aratana Chief Commercial Officer, stated “we’re very pleased about the reactions, questions and excitement shown within the CE sessions and the follow-up booth activity with these first-in-class therapeutics.”

To view studies and observations relating to new therapeutics in development, please go to

Recent News Posts

View All